Also Included In: Neurology / Neuroscience; Alcohol / Addiction / Illegal Drugs
Article Date: 17 Nov 2011 - 0:00 PST
email to a friend 
printer friendly 
opinions 
In this week's PLoS Medicine, Shekhar Saxena of the WHO in Geneva, Switzerland and colleagues summarize the recent WHO Mental Health Gap Action Programme (mhGAP) intervention guide that provides evidence-based management recommendations for mental, neurological, and substance use (MNS) disorders.
This guide is aimed at reducing the treatment gap for MNS disorders, which is more than 75% in many low- and middle-income countries (LMICs). Further details and background material to the guide can be accessed on the WHO website: http://bit.ly/vKPSRF
The authors recommend that: "In the near future, further efforts should be made to introduce formal evaluations of the capability of [treatment] programs to induce relevant and persistent changes, and to generate useful insights on how implementation in [low- and middle-income countries] should be conducted to maximize benefit at sustainable costs."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our mental health section for the latest news on this subject. The PLoS Medicine Mental Health in Low- and Middle-Income Countries Collection, a seven-part series of articles published between October 2009 and February 2010, provides further information on mental, neurological, and substance-use disorders in LMICs.
Funding: Funding for the mhGAP Programme, under which the work reported in this manuscript was done, was provided by the following: American Psychiatric Foundation, USA; Association of Aichi Psychiatric Hospitals, Japan; Autism Speaks, USA; CBM; Government of Italy; Government of Japan; Government of The Netherlands; International Bureau for Epilepsy; International League Against Epilepsy; Medical Research Council, UK; National Institute of Mental Health, USA; Public Health Agency of Canada, Canada; Rockefeller Foundation, USA; Shirley Foundation, UK; Syngenta, Switzerland; United Nations Population Fund;World Psychiatric Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JLA was paid in 2007 by Lundbeck S.A. for consultancy preparation of the research protocol for a study on the diagnostic delay in first episode of depression in contact with health care centers in Spain and was paid in 2009 by Sanofi Aventis S.A. for expert testimony on the side effects of veralapride. OO is the current President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) (http://www.iacapap.org/). JWS served on scientific advisory boards for GlaxoSmithKline (2010), Eisai (2009), and UCB (2009); received funding for travel from UCB (2008) and Janssen (2009); serves on the editorial boards of Lancet Neurology, Epilepsia and Epileptic Disorders; served on the speaker's bureaus of UCB (2009) and GlaxoSmithKline (2009); and has received research support from UCB (grant finished 2010), Eisai (grant finished 2008), the NIH (ongoing grant), the EU FP7 (ongoing grant), the Wellcome Trust (grant finished 2009), WHO (ongoing grant), the National Epilepsy Funds of the Netherlands (ongoing grant), and the Epilepsy Society (ongoing grant). His current position is endowed by the National Society for Epilepsy (UK). SS confirms that the competing interests of JWS were declared, reviewed, and deemed acceptable by the mhGAP Guideline Development Group. All other authors have declared that no competing interests exist.
Citation: Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, et al. (2011) Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. PLoS Med 8(11): e1001122. doi:10.1371/journal.pmed.1001122
Public Library of Science Please use one of the following formats to cite this article in your essay, paper or report:
MLA
9 Dec. 2011.
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
